Overview

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

Status:
Completed
Trial end date:
2023-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Impax Laboratories, LLC
Treatments:
Carbidopa
Moxifloxacin